
Kimberly Chong
Examiner (ID: 8669, Phone: (571)272-3111 , Office: P/1674 )
| Most Active Art Unit | 1635 |
| Art Unit(s) | 1636, 1635, 1674 |
| Total Applications | 2007 |
| Issued Applications | 1153 |
| Pending Applications | 209 |
| Abandoned Applications | 674 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 16168219
[patent_doc_number] => 10709759
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2020-07-14
[patent_title] => Self-replicating cell selective gene delivery compositions, methods, and uses thereof
[patent_app_type] => utility
[patent_app_number] => 16/247022
[patent_app_country] => US
[patent_app_date] => 2019-01-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 34
[patent_figures_cnt] => 53
[patent_no_of_words] => 18655
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 91
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16247022
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/247022 | Self-replicating cell selective gene delivery compositions, methods, and uses thereof | Jan 13, 2019 | Issued |
Array
(
[id] => 17875772
[patent_doc_number] => 11447775
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-09-20
[patent_title] => Antisense oligonucleotides targeting alpha-synuclein and uses thereof
[patent_app_type] => utility
[patent_app_number] => 16/961624
[patent_app_country] => US
[patent_app_date] => 2019-01-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 16
[patent_figures_cnt] => 28
[patent_no_of_words] => 18633
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 28
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16961624
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/961624 | Antisense oligonucleotides targeting alpha-synuclein and uses thereof | Jan 10, 2019 | Issued |
Array
(
[id] => 17548470
[patent_doc_number] => 20220119811
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-04-21
[patent_title] => ALPHA-SYNUCLEIN ANTISENSE OLIGONUCLEOTIDES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 15/733369
[patent_app_country] => US
[patent_app_date] => 2019-01-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 48640
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15733369
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/733369 | ALPHA-SYNUCLEIN ANTISENSE OLIGONUCLEOTIDES AND USES THEREOF | Jan 10, 2019 | Abandoned |
Array
(
[id] => 19666135
[patent_doc_number] => 12178855
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-12-31
[patent_title] => Compositions and methods for facilitating delivery of synthetic nucleic acids to cells
[patent_app_type] => utility
[patent_app_number] => 16/961187
[patent_app_country] => US
[patent_app_date] => 2019-01-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 21
[patent_no_of_words] => 26064
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 122
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16961187
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/961187 | Compositions and methods for facilitating delivery of synthetic nucleic acids to cells | Jan 9, 2019 | Issued |
Array
(
[id] => 16728128
[patent_doc_number] => 20210095275
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-01
[patent_title] => OLIGONUCLEOTIDES FOR MODULATING GSK3B EXPRESSION
[patent_app_type] => utility
[patent_app_number] => 15/733368
[patent_app_country] => US
[patent_app_date] => 2019-01-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23973
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 62
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15733368
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/733368 | OLIGONUCLEOTIDES FOR MODULATING GSK3B EXPRESSION | Jan 9, 2019 | Abandoned |
Array
(
[id] => 16728127
[patent_doc_number] => 20210095274
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-01
[patent_title] => OLIGONUCLEOTIDES FOR MODULATING PIAS4 EXPRESSION
[patent_app_type] => utility
[patent_app_number] => 15/733367
[patent_app_country] => US
[patent_app_date] => 2019-01-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21926
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 78
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15733367
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/733367 | OLIGONUCLEOTIDES FOR MODULATING PIAS4 EXPRESSION | Jan 7, 2019 | Abandoned |
Array
(
[id] => 18762901
[patent_doc_number] => 11813280
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-11-14
[patent_title] => Reducing beta-catenin and IDO expression to potentiate immunotherapy
[patent_app_type] => utility
[patent_app_number] => 16/958969
[patent_app_country] => US
[patent_app_date] => 2019-01-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 23
[patent_figures_cnt] => 32
[patent_no_of_words] => 24568
[patent_no_of_claims] => 40
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 52
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16958969
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/958969 | Reducing beta-catenin and IDO expression to potentiate immunotherapy | Jan 2, 2019 | Issued |
Array
(
[id] => 14581895
[patent_doc_number] => 20190218556
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-07-18
[patent_title] => COMPOSITIONS AND METHODS OF INHIBITING GENE EXPRESSION IN A LUNG
[patent_app_type] => utility
[patent_app_number] => 16/233346
[patent_app_country] => US
[patent_app_date] => 2018-12-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10169
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 31
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16233346
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/233346 | COMPOSITIONS AND METHODS OF INHIBITING GENE EXPRESSION IN A LUNG | Dec 26, 2018 | Abandoned |
Array
(
[id] => 14625193
[patent_doc_number] => 20190225964
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-07-25
[patent_title] => MODULATION OF EXON RECOGNITION IN PRE-MRNA BY INTERFERING WITH THE SECONDARY RNA STRUCTURE
[patent_app_type] => utility
[patent_app_number] => 16/230927
[patent_app_country] => US
[patent_app_date] => 2018-12-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14712
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16230927
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/230927 | MODULATION OF EXON RECOGNITION IN PRE-MRNA BY INTERFERING WITH THE SECONDARY RNA STRUCTURE | Dec 20, 2018 | Abandoned |
Array
(
[id] => 20316738
[patent_doc_number] => 12455284
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-10-28
[patent_title] => Double-stranded DNA molecule for the detecting and characterizing molecular interactions
[patent_app_type] => utility
[patent_app_number] => 16/955596
[patent_app_country] => US
[patent_app_date] => 2018-12-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 22
[patent_figures_cnt] => 18
[patent_no_of_words] => 30790
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 86
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16955596
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/955596 | Double-stranded DNA molecule for the detecting and characterizing molecular interactions | Dec 20, 2018 | Issued |
Array
(
[id] => 16930938
[patent_doc_number] => 20210196827
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-01
[patent_title] => FUNCTIONAL NUCLEIC ACID HAVING NUCLEOSIDE ANALOG DRUG INTEGRATED INTO SKELETON, DERIVATIVE AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/057525
[patent_app_country] => US
[patent_app_date] => 2018-12-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6469
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17057525
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/057525 | FUNCTIONAL NUCLEIC ACID HAVING NUCLEOSIDE ANALOG DRUG INTEGRATED INTO SKELETON, DERIVATIVE AND USE THEREOF | Dec 13, 2018 | Abandoned |
Array
(
[id] => 20106955
[patent_doc_number] => 12357653
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-07-15
[patent_title] => Compositions comprising circular polyribonucleotides and uses thereof
[patent_app_type] => utility
[patent_app_number] => 16/772678
[patent_app_country] => US
[patent_app_date] => 2018-12-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 61
[patent_figures_cnt] => 63
[patent_no_of_words] => 48663
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 82
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16772678
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/772678 | Compositions comprising circular polyribonucleotides and uses thereof | Dec 13, 2018 | Issued |
Array
(
[id] => 18467092
[patent_doc_number] => 20230201373
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-29
[patent_title] => CRISPR-MEDIATED GENOME EDITING WITH VECTORS
[patent_app_type] => utility
[patent_app_number] => 16/954171
[patent_app_country] => US
[patent_app_date] => 2018-12-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22557
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 81
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16954171
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/954171 | CRISPR-MEDIATED GENOME EDITING WITH VECTORS | Dec 13, 2018 | Pending |
Array
(
[id] => 14130229
[patent_doc_number] => 20190099504
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-04-04
[patent_title] => METHOD FOR DELIVERY OF BIOLOGICAL MOLECULE TO NERVOUS TISSUE
[patent_app_type] => utility
[patent_app_number] => 16/217962
[patent_app_country] => US
[patent_app_date] => 2018-12-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11418
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 40
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16217962
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/217962 | Method for delivery of biological molecule to nervous tissue | Dec 11, 2018 | Issued |
Array
(
[id] => 19258209
[patent_doc_number] => 12018255
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-06-25
[patent_title] => Compositions and methods for treating disorders of genomic imprinting
[patent_app_type] => utility
[patent_app_number] => 16/770877
[patent_app_country] => US
[patent_app_date] => 2018-12-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 25
[patent_figures_cnt] => 29
[patent_no_of_words] => 24874
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 71
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16770877
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/770877 | Compositions and methods for treating disorders of genomic imprinting | Dec 6, 2018 | Issued |
Array
(
[id] => 16105717
[patent_doc_number] => 10695443
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-06-30
[patent_title] => Exosome transfer of nucleic acids to cells
[patent_app_type] => utility
[patent_app_number] => 16/201937
[patent_app_country] => US
[patent_app_date] => 2018-11-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4875
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 68
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16201937
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/201937 | Exosome transfer of nucleic acids to cells | Nov 26, 2018 | Issued |
Array
(
[id] => 14043971
[patent_doc_number] => 20190078092
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-03-14
[patent_title] => PREVENTING TUMOR DEVELOPMENT AND METASTASIS
[patent_app_type] => utility
[patent_app_number] => 16/200508
[patent_app_country] => US
[patent_app_date] => 2018-11-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9579
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 53
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16200508
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/200508 | Preventing tumor development and metastasis | Nov 25, 2018 | Issued |
Array
(
[id] => 16885750
[patent_doc_number] => 20210171945
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-10
[patent_title] => METHODS OF MODULATING ANTISENSE ACTIVITY
[patent_app_type] => utility
[patent_app_number] => 16/762734
[patent_app_country] => US
[patent_app_date] => 2018-11-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17195
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -46
[patent_words_short_claim] => 31
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16762734
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/762734 | METHODS OF MODULATING ANTISENSE ACTIVITY | Nov 15, 2018 | Abandoned |
Array
(
[id] => 16613969
[patent_doc_number] => 20210032622
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-04
[patent_title] => SELF-INACTIVATING (SIN) CRISPR/CAS OR CRISPR/CPF1 SYSTEMS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/762444
[patent_app_country] => US
[patent_app_date] => 2018-11-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 54765
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -38
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16762444
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/762444 | SELF-INACTIVATING (SIN) CRISPR/CAS OR CRISPR/CPF1 SYSTEMS AND USES THEREOF | Nov 8, 2018 | Abandoned |
Array
(
[id] => 15895199
[patent_doc_number] => 20200147118
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-14
[patent_title] => COMPOSITIONS AND METHODS FOR DETECTION, RISK ASSESSMENT AND TREATMENT OF DIABETES, OBESITY, AND INFLAMMATION
[patent_app_type] => utility
[patent_app_number] => 16/186423
[patent_app_country] => US
[patent_app_date] => 2018-11-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23738
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 92
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16186423
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/186423 | COMPOSITIONS AND METHODS FOR DETECTION, RISK ASSESSMENT AND TREATMENT OF DIABETES, OBESITY, AND INFLAMMATION | Nov 8, 2018 | Abandoned |